Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
976 12 |
Ultima descărcare din IBN: 2023-10-20 08:26 |
Căutarea după subiecte similare conform CZU |
616.36-002-085 (7) |
Pathology of the digestive system. Complaints of the alimentary canal (1732) |
SM ISO690:2012 MUNTEAN, Valeria, ŢURCANU, Adela, TCACIUC, Eugen. Efficacy of Interferonfree treatment for patients with chronic hepatitis C virus. In: Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale, 2019, nr. 2(62), pp. 147-150. ISSN 1857-0011. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Buletinul Academiei de Ştiinţe a Moldovei. Ştiinţe Medicale | ||||||
Numărul 2(62) / 2019 / ISSN 1857-0011 | ||||||
|
||||||
CZU: 616.36-002-085 | ||||||
Pag. 147-150 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
The new direct-acting antiviral agents (DAA) have revolutionised the treatment of patients with chronic hepatitis C virus (HCV) infection. With the development of new potent DAA and the approval of different DAA combinations, cure rates of HCV infection of >90% are achievable for almost all HCV genotypes and stages of liver disease. Currently available DAA target different steps in the HCV replication cycle, in particular the NS3/4A protease, the NS5B polymerase, and the NS5A replication complex. Treatment duration varies between 8 and 24 weeks depending on the stage of fibrosis, prior treatment, HCV viral load, and HCV genotype. Ribavirin is required only for some treatment regimens and may be particularly beneficial in patients with cirrhosis. Conclusion: With the new, almost side effect-free DAA treatment options chronic HCV infection became a curable disease |
||||||
Cuvinte-cheie viral hepatitis C, direct-acting antiviral agents, DAA, treatment, hepatita virală C, agenți antivirali cu acțiune directă, DAA, Tratament, вирусный гепатит С, противовирусные препараты прямого действия, DAA, лечение |
||||||
|